News

An extension of a pivotal phase 3 trial shows that the functional and anatomic benefits of Eylea HD (aflibercept 8 milligram dose) have staying power in people with neovascular (wet) age-related ...
A new analysis finds that prior authorization for anti-VEGF therapies increases societal costs despite minimal insurer savings, burdening patients, workplaces, and providers.
Fluid resolution at week 4 seems to translate into longer dosing intervals at week 96 of the PULSAR trial that assessed Eylea ...
Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...
Homecare Homebase revealed over 4 million patients are denied home health services annually, highlighting critical access issues and the impact of proposed Medicare cuts.
Small doses of the involuntary nervous system blocker, atropine, may offer a non-invasive treatment for symptomatic vitreous ...
Most of the attention has been on Medicaid cuts, but the reconciliation bill and CMS rule changes will also slash enrollment ...
In a study in mice, a wireless implant was able to release glucagon as an emergency treatment for hypoglycemia, a serious ...
IRX-101, a new antiseptic tested in patients receiving eye injections for macular degeneration, resulted in less pain and ...
New findings reveal that early treatment with Syfovre significantly improves vision preservation in geographic atrophy ...
More than 60 companies pledged to improve healthcare technology during a White House “Make Health Tech Great Again” event ...
Anti-VEGF and anti-complement therapies work on distinct mechanisms in age-related macular degeneration, and both may be ...